Merck

Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
BioSpace
Mon, 10/14/19 - 09:30 am
Genentech
Pfizer
Merck
Amgen
Novartis
Merck CEO: Stepping down from Trump council was 'not a political issue'
Yahoo Finance
Fri, 10/11/19 - 10:30 am
Merck
Ken Frazier
Pharma CEOs
Donald Trump
Merck CEO: When it comes to drug pricing and politics, pharma's in the 'crosshairs'
Fierce Pharma
Thu, 10/10/19 - 07:47 pm
drug pricing
Ken Frazier
Merck
Pharma CEOs
Big Pharma giving more money to patient advocacy groups
Beckers Hospital Review
Wed, 10/9/19 - 11:15 pm
Big Pharma
JNJ
AbbVie
Bristol-Myers Squibb
Pfizer
Merck
AstraZeneca
patient advocacy groups
Amid next-gen vaccine race, Merck says ex-employee bolted to Pfizer with 'thousands' of key documents
Fierce Pharma
Wed, 10/9/19 - 11:00 pm
Merck
Pfizer
vaccines
trade secrets
pneumococcal disease
Merck taps 4D pharma for bacterial vaccine R&D project
Fierce Biotech
Tue, 10/8/19 - 09:51 am
Merck
4D Pharma
vaccines
R&D
Recent Job Cuts in the Biopharma Industry
BioSpace
Mon, 10/7/19 - 11:29 pm
Tocagen
Sanofi
Amneal
Daiichi Sankyo
Integra Life Sciences
Aclaris
Bayer
Novartis
Illumina
Merck
Roche Molecular Systems
Prometheus Labs
layoffs
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Fierce Pharma
Fri, 10/4/19 - 12:44 pm
Merck
Keytruda
Bristol-Myers Squibb
Pfizer
Eliquis
AbbVie
Humira
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Pharmaceutical Business Review
Thu, 10/3/19 - 10:37 am
Merck
Keytruda
China
non-small cell lung cancer
Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019
Fierce Pharma
Wed, 10/2/19 - 10:53 am
JNJ
Takeda
parents
Eli Lilly
Merck
Novo Nordisk
Sanofi
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
Tue, 10/1/19 - 10:29 am
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Merck’s Recarbrio Shows Success in Late-Stage Trial for HABP/VABP Patients
BioSpace
Tue, 10/1/19 - 12:10 am
Merck
Recarbio
HABP/VABP
hospital-acquired bacterial pneumonia
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
Fierce Pharma
Sun, 09/29/19 - 09:37 pm
Merck
Eisai
Keytruda
Lenvima
endometrial cancer
ESMO
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
Sat, 09/28/19 - 05:00 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Sat, 09/28/19 - 04:49 pm
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
Motley Fool
Fri, 09/27/19 - 09:10 am
diabetes
Eli Lilly
Merck
Novo Nordisk
GSK
Byetta
Victoza
Bydureon
Ozempic
Tanzeum
Trulicity
Rybelsus
Merck, Pfizer execs explain how they tap sites for cancer trials
Biopharma Dive
Tue, 09/24/19 - 07:04 pm
cancer
clinical trials
Pfizer
Merck
immuno-oncology
Bavencio
Keytruda
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Investors Business Daily
Sat, 09/21/19 - 12:28 pm
Wave Life Sciences
suvodirsen
DMD
Merck
Keytruda
Biogen
Spinraza
Zoetis
Europe
animal health
Jazz Pharmaceuticals
JZP-258
narcolepsy
Themis raises €40M to run phase 3 chikungunya vaccine trial
Fierce Biotech
Wed, 09/18/19 - 10:04 am
Themis
Merck
chikungunya virus
vaccines
clinical trials
Merck, Eisai's Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and Australia
Fierce Pharma
Wed, 09/18/19 - 09:56 am
Merck
Keytruda
Eisai
Lenvima
endometrial cancer
Canada
Australia

Pages